OrganOx Opens State-of-the-Art Research, Development, and Production Headquarters in Oxford, UK
May 22 2024 - 3:00AM
Business Wire
OrganOx Ltd, a world-leading medical technology company
developing innovative solutions for organ preservation prior to
transplantation, and for the treatment of acute organ failure, is
proud to announce the official opening of a new 18,000 square-foot
global research, development, and production headquarters in
Oxford, UK. Originally spun out from the University of Oxford in
2008, OrganOx developed the world’s first normothermic liver
perfusion device, the metra®. The metra® launched across Europe in
2018 and in the U.S. in 2022 and has gained rapid market adoption
since, enabling more organ transplants, eradicating night-time
operating, and improving patient outcomes.
“Our new facility opening is a major milestone, providing
OrganOx stakeholders access to world-class facilities and
technologies as we work together in ways that were simply not
possible previously,” said Craig Marshall, CEO. “We are proud to be
a growing member of the Oxford business and scientific community,
and I am greatly looking forward to broader collaborations with
commercial and clinical partners.”
Prof. Peter Friend, FMedSci, Chief Medical Officer, and
Co-Founder of OrganOx, commented, “We are all excited about what
the future holds for OrganOx as we continue to push the scientific
and clinical boundaries with technology-based solutions designed to
improve the lives of patients experiencing acute or chronic organ
failure. This remarkable new facility will support us in that
mission for many years to come.”
“Peter and I, surgeon and engineer, could scarcely imagine a day
like this when we first began collaborating in an Oxford University
laboratory more than 20 years ago,” said Prof. Constantin Coussios,
OBE FREng FMedSci, Chief Technology Officer, and Co-Founder of
OrganOx. “It is truly remarkable and a testament to the dedication
and efforts of a great many researchers, engineers, transplant
surgeons, staff, customers, patients, and business partners, whom
we celebrate on this occasion.”
About OrganOx
OrganOx is a commercial stage UK-based medical device company
with a focus on the therapeutic applications of isolated organ
perfusion, spun out of the University of Oxford in 2008. Its first
product, the OrganOx metra® normothermic liver machine perfusion
system, has been used to support more than 4,000 liver transplant
operations globally, optimising the use of donated organs by
enabling assessment of the quality of livers as well as longer
preservation durations. Other therapeutic applications, including
in kidney transplantation, are in development. Learn more at
www.organox.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240522683590/en/
Investor Relations: Steve Deitsch Chief Financial
Officer, OrganOx investorrelations@organox.com Media: Jenna
Kane Health+Commerce jennakane@healthandcommerce.com